Most Popular Stories
Poll
Featured Jobs
-
Chief Privacy Officer, Americas Region
IMS Health Incorporated - Plymouth Meeting, PA -
Texas OB/GYN
StaffPointe, LLC - Dallas, TX -
Washington Pediatrician
StaffPointe, LLC - near Seattle, WA -
Missouri Hematologist/Oncologist
StaffPointe, LLC - southeast, MO -
California Internal Medicine
StaffPointe, LLC - near San Diego , CA
Events
- World Healthcare Innovation & Technology Congress WHIT v.4.0
Dec 8-10 — Washington, DC - World Health Care Congress
April 14-16, 2009 — Washington, DC
Paid Research Reports
- Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard
- Impact of Pharmacogenomics on Public Healthcare Policy
- The Cardiovascular Disorders Market Outlook to 2012
- 2008 Trends to Watch: Pharmaceutical Technology
- Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies
Popular Topics
Boston ends Canadian drug import program, citing lack of interest
Nationally, programs offering lower-cost Canadian prescription drugs have raised headlines, moving ahead despite federal authorities saying that doing so wasn't kosher. Four years ago, Boston Mayor Thomas Menino was one of those who took a stand, offering such drugs to employees and retirees. He followed in the footsteps of several other mayors launching drug reimportation programs, including the mayor of Springfield, MA.
In this case, however, it doesn't seem to have impressed them. The program is now ending, having never attracted more than a handful of participants. City officials say that there's been a lack of interest from eligible city retirees, many of whom are more interested in leveraging U.S. generic offerings, web-based Canadian pharmacies and generic drug programs. However, one city council member contends that the city was forced to abandon the program due to pressure from the FDA, which strong opposes such efforts.
To learn more about the program's end:
- read this piece from the Boston Globe
Related Article:
Reimportation issue makes a comeback in Senate
Related Stories
- FTC: Pharmas cut 14 deals to delay generic sales in '07
- FDA says hospitals may still have recalled heparin
- SPOTLIGHT: Should FDA's info be in all DTC ads?
- SPOTLIGHT: FDA needs database update, more staff, leaders say
- Biotechs eager for FDA approval of biogeneric drugs
- Vytorin, Avandia raise doubt on FDA approvals
- Did pharma ask the FDA for off-label rule change?
- FDA to further investigate anemia drug risks
- Statin drug probably not going OTC
- FDA rejects Avastin for breast cancer treatment
Comments
Post new comment
Home
| Subscribe | Advertise | Mobile Edition | RSS |
Privacy
| Site MapTHE FIERCEMARKETS NETWORKFierceFinance | FierceFinanceIT | FierceSarbox | FierceHealthcare | FierceHealthFinance | FierceHealthIT | Hospital Impact | FierceCIO | FierceCIO:TechWatch | FierceContentManagement | FierceMobileIT | FierceBiotech | FierceBioResearcher | FiercePharma | FierceVaccines | FierceIPTV | FierceOnlineVideo | FierceTelecom | FierceVoIP | FierceBroadbandWireless | FierceDeveloper | FierceMobileContent | FierceWireless | FierceWireless:Europe© 2008 FierceMarkets, Inc. All rights reserved. |
![]() |





